THURSDAY, Sept. 9 (HealthDay News) -- A baseline panel of oxidative biomarkers and lipoprotein(a) (Lp[a]) in healthy subjects can be combined with traditional risk factors to better estimate coronary artery disease (CAD) risk, according to a study in the Sept. 14 issue of the Journal of the American College of Cardiology.
Sotirios Tsimikas, M.D., of the University of California San Diego in La Jolla, and colleagues studied a cohort of 45- to 79-year-old, apparently healthy participants in the European Prospective Investigation of Cancer study, for whom baseline levels of oxidized phospholipids on apolipoprotein B-100 particles and Lp(a) had been obtained. The cohort was followed for approximately six years, and 763 subjects who developed fatal or nonfatal CAD were compared to 1,397 sex- and age-matched subjects without CAD who were enrolled at the same time.
Following adjustment for age, smoking, low- and high-density lipoprotein cholesterol, diabetes, and systolic blood pressure, the researchers found the CAD event risk to be significantly associated with the highest tertiles of baseline oxidized phospholipids on apolipoprotein B-100 particles (odds ratio, 1.67) and Lp(a) (odds ratio, 1.64) compared with the lowest tertiles. When the oxidative biomarkers were added to Framingham Risk Score (FRS) in a CAD risk model, the model's predictive value was increased.
"Oxidation-specific biomarkers are strongly associated with CAD events and can be a useful adjunct to traditional risk factors or FRS in risk prediction of future CAD in initially healthy subjects," the authors write.
Several study authors reported inventing patented processes for the clinical use of oxidation-specific antibodies and other factors in cardiovascular diagnosis and prognosis, or having ties to Atherotope Inc. or ATEROVAX.
Abstract
Full Text (subscription or payment may be required)
